Testing apixaban alone or with clopidogrel after stroke linked to atrial fibrillation
Tests apixaban with or without clopidogrel in people with stroke, atrial fibrillation and arterial narrowing.
Key facts
- Who runs it
- Yonsei University
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral Atherosclerosis
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 586 people, planned
- Started
- 14 Jul 2026
- Expected to end
- Oct 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Apixaban
- Clopidogrel
- Record updated
- 16 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a new ischemic stroke, non-valvular atrial fibrillation and significant atherosclerosis in brain or aortic arteries. It compares apixaban alone with apixaban plus clopidogrel for 30 days.
- Age
- 19 years or older
- Sex
- Women and men can join.
- Disease stage
- Acute ischemic stroke confirmed by brain MRI, with symptoms within 5 days before randomization. Non-valvular atrial fibrillation documented by ECG or medical records. Significant atherosclerosis in brain or aortic arch arteries: at least 30% narrowing, high-risk plaque, or complex aortic plaque.
- Earlier treatment
- The stroke must not have happened while taking both a NOAC and antiplatelet therapy. People who need antiplatelet drugs other than clopidogrel cannot join.
Main reasons for not taking part
- Mechanical heart valve or rheumatic mitral stenosis
- Bleeding in the brain, or hemorrhagic change of the stroke
- Severe kidney or liver problems
- Small-vessel (lacunar) stroke
- Pregnant or breastfeeding women
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- Adults aged 19 years or older at the time of enrollment
- Patients with non-valvular atrial fibrillation (NVAF) documented by electrocardiography or medical records
- Acute ischemic stroke confirmed by brain MRI (diffusion-weighted and FLAIR sequences), with neurological symptoms occurring within 5 days prior to randomization
- Presence of clinically significant atherosclerosis in the cerebral or aortic arteries, meeting at least one of the following criteria:; ① ≥30% stenosis in the relevant artery (the artery supplying the infarcted territory) demonstrated by CTA, MRA, or DSA - using the WASID criteria for intracranial arteries and NASCET criteria for extracranial arteries; ② High-risk atherosclerotic plaque features in the relevant artery demonstrated by CTA, MRA, or ultrasound, such as ulceration, intraplaque hemorrhage, mobile plaque, or a large lipid core (involving ≥25% of plaque cross-sectional area) on CTA/MRA, or ulceration, mobile plaque, or hypoechoic/echolucent plaque on ultrasound; or presence of branch artery occlusive disease (BAOD); ③ Complex aortic plaque (≥4 mm in thickness, mobile, or ulcerative) identified in the ascending aorta or aortic arch by transthoracic/transesophageal echocardiography or coronary CT angiography
- Ability and willingness to provide written informed consent for participation in the study
Who cannot take part
- Planned percutaneous coronary intervention, coronary artery bypass graft surgery, carotid endarterectomy, or intracranial stenting within 3 months after enrollment
- Ischemic stroke occurring despite concurrent use of both NOAC and antiplatelet therapy
- Concomitant use of strong CYP3A4 and P-glycoprotein inhibitors that can significantly increase apixaban exposure (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin)
- Concomitant use of strong CYP2C19 inducers that can reduce clopidogrel antiplatelet effect (e.g., rifampin, carbamazepine, phenytoin, phenobarbital, St. John's wort)
- Participation in another interventional clinical trial within the past 30 days or concurrent participation in another interventional study (non-interventional observational or registry studies may be allowed at the investigator's discretion)
- Presence of mechanical heart valves or rheumatic mitral stenosis
- Presence of mural thrombus in the heart confirmed by imaging
- History within the past 30 days of gastrointestinal bleeding, vascular malformation of the brain or spinal cord, recent brain, spinal, or ophthalmologic surgery or trauma, esophageal varices, or intracranial hemorrhage at any time; or chronic regular use of NSAIDs (≥3 days per week for ≥2 consecutive weeks)
- Planned surgery or high-bleeding-risk procedure within 3 months, or presence of active bleeding at enrollment
- Pre-stroke modified Rankin Scale (mRS) ≥ 2
- Severe comorbid illness or malignancy not in complete remission with an expected life expectancy <1 year
- Known hypersensitivity or allergy to apixaban or clopidogrel
- Intracranial hemorrhage or hemorrhagic transformation (PH1 or PH2) according to ECASS criteria
- Any other condition that, in the investigator's judgment, would make participation or continued involvement in the study inappropriate or infeasible
- Renal impairment with creatinine clearance ≤30 mL/min/1.73 m²
- Severe hepatic impairment, including acute hepatitis, chronic active hepatitis, hepatic lesions or coagulopathy, hepatic failure, or laboratory evidence of AST/ALT >2× the upper limit of normal (ULN) or total bilirubin >1.5× ULN
- Anemia (hemoglobin < 8.0 g/dL) or thrombocytopenia (platelet count < 100,000/µL)
- Uncontrolled diabetes mellitus (HbA1c > 10.0%) or severe hypertension (systolic ≥ 220 mmHg or diastolic ≥ 120 mmHg)
- Requirement for antiplatelet agents other than clopidogrel
- Small-vessel occlusion (lacunar infarction) according to the TOAST classification
- Pregnant or breastfeeding women
- Clinically significant mass effect due to space-occupying cerebral infarction, or patients expected to require decompressive craniectomy, including those with midline shift > 5 mm, loss of basal cisterns, herniation, fourth-ventricle compression, or obstructive hydrocephalus in posterior fossa infarcts
Where in South Korea
- Yonsei University College of MedicineSeoul, South KoreaContact: Young Dae Kim, ProfessorTaking people
About the trial
What the trial wants to find out
This trial aims to compare the safety and efficacy of apixaban alone versus apixaban combined with clopidogrel in patients with acute ischemic stroke associated with non-valvular atrial fibrillation and concomitant symptomatic intracranial or extracranial atherosclerosis. Participants will be randomly assigned in a 1:1 ratio to receive apixaban monotherapy or dual therapy with clopidogrel for 30 days. The primary outcome is the incidence of new symptomatic or asymptomatic ischemic lesions on DWI/FLAIR at 30 (±5) days compared with baseline MRI, adjudicated by a central committee.
The 2 groups in the trial
- Apixaban and Clopidogrel Combination TherapyTreatment being tested
Participants receive apixaban(5mg twice daily, or 2.5mg twice daily if indicated) plus clopidogrel 75mg daily for 30days, followed by apixaban monotherapy thereafter.
Treatment: Apixaban
- Apixaban MonotherapyExisting treatment, for comparison
Participants receive apixaban 5mg(or 2.5mg if indicated) twice daily as monotherapy for 30 days and continue apixaban monotherapy thereafter.
Treatment: Clopidogrel
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter Prospective Randomized Study to Evaluate the Efficacy of Apixaban and Clopidogrel on the Prevention of Recurrent Ischemic Stroke in Patients With Atrial Fibrillation and Cerebral Atherosclerosis
- Plain-language title
- Testing apixaban alone or with clopidogrel after stroke linked to atrial fibrillationGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 16 October 2026